Introduction {#Sec1}
============

Precision medicine aims to finely select treatments for cancer based on the genetic information of individual patients^[@CR1]^. One of the highly critical problems in precision medicine is predicting anticancer drug response for each patient^[@CR2]--[@CR4]^. Due to the heterogeneity of tumors, the patients with the same type of cancer may show various therapeutic responses toward similar drugs^[@CR5]^. Therefore, providing computational methods to discover the relationship between genomic information and drug sensitivity is of high importance and can be beneficial in precision medicine^[@CR3],[@CR6]^.

Genomics of Drug Sensitivity in Cancer (GDSC)^[@CR7]^ and Cancer Cell Line Encyclopedia (CCLE)^[@CR8]^ are two projects that have provided molecular profiles and drug response values for hundreds of cancer cell lines against several anticancer drugs. These large datasets facilitate the development of computational methods for anticancer drug sensitivity prediction. Numerous computational methods have been proposed to predict drug response using gene expression profile, or other molecular information of cell lines. Some of the computational methods have considered drug information such as chemical substructure of drugs, besides made use of cell line information. In the proposed computational methods, various machine learning methods have been utilized such as sparse linear regression^[@CR4],[@CR9]--[@CR11]^, random forest^[@CR2],[@CR12],[@CR13]^, kernel-based methods^[@CR4],[@CR14]--[@CR17]^, matrix factorization^[@CR1],[@CR18]--[@CR20]^, neural networks and deep learning^[@CR21]--[@CR24]^.

Wang et al. have proposed a Similarity Regularized Matrix Factorization (SRMF) method, which utilizes the similarity of cell lines based on gene expression profiles and chemical substructure similarity of drugs to predict anticancer drug sensitivity^[@CR1]^. They also conducted drug-repurposing and suggested new potential treatments for cell lines with Non-small Cell Lung Cancer (NSCL). It is suggested that patients who have similar genomic properties reveal similar responses to similar drugs^[@CR1]^. Based on the SRMF study, Suphavilai et al. have proposed a recommender system called "CaDRReS" that can predict drug response for unseen cell lines^[@CR19]^. Furthermore, they showed that latent space features are correlated with associated pathways of drugs. They did not consider any features of drugs for predicting the drug response values. Afterwards, Chang et al. have devised "CDRscan", an ensemble model containing five Convolutional Neural Networks (CNNs)^[@CR21]^. They made use of mutational profiles of cell lines and chemical substructure of drugs as the input features to these CNNs. The drug response values were measured by averaging the output of five CNNs. Moreover, they have repurposed multiple non-oncology drugs as the potential therapeutic agents for cancer cell lines. Recently, Wei et al. have suggested a simple cell line-drug complex network called "CDCN"^[@CR25]^. They constructed a complex network from various information, including cell line similarities, drug similarities, and drug responses, and inferred unknown drug response from the network. They also proposed a generalized version that can predict the drug response for new drugs and new cell lines. Despite its simple structure, CDCN had satisfying results in imputing missing drug responses.

Nevertheless, the proposed methods had moderate performance and do not analyze several types of features for cell lines and drugs. Thus, investigating the influence of various features for cell lines and drugs in predicting therapeutic response is still in need and challenging. We investigate three types of cell line features, namely gene expression, mutation profile, and copy number variation, in addition to three types of drug features, including chemical substructure, target proteins, and associated KEGG pathways. In this work, we propose ADRML, Anticancer Drug Response Prediction, by using Manifold Learning. ADRML constructs a bipartite graph between drug and cell lines, and then decompose its adjacency matrix using similarity-constrained manifold learning into two lower-dimensional latent matrices. The proposed method is capable of predicting therapeutic response for new cell lines and new drugs. The similarity-constrained manifold learning previously has been used in the context of drug-disease association prediction^[@CR26]^ and drug--drug interaction prediction^[@CR27]^, which yielded accurate performance.

The performance of ADRML is measured using various types of cell line similarities and drug similarities and is compared to the recently proposed methods on both GDSC and CCLE datasets. Moreover, the rationality of ADRML predictions is confirmed by analyzing the association between the predicted drug response values and activity scores of Biocarta pathways. Finally, conducting case studies on the predictions of ADRML for unknown drug response in literature and reliable databases verifies its capability in predicting unknown drug response and admits that ADRML obtains accurate results for new pairs of cell line-drug.

Results {#Sec2}
=======

Benchmark datasets and collected features {#Sec3}
-----------------------------------------

In this work, we used two pharmacogenomic datasets, namely the Genomics of Drug Sensitivity in Cancer (GDSC)^[@CR7]^ and Cancer Cell Line Encyclopedia (CCLE)^[@CR8]^. Among several types of data in these datasets, various information including the half-maximal inhibitory concentration (*IC*50), the gene expression profile, copy number variation, and mutation profile was downloaded by using *PharmacoGx* R package^[@CR28]^. The collected genes were accessible in the COSMIC database^[@CR29]^, and the collected drugs were restricted to the drugs with a Compound ID (CID) in the PubChem database^[@CR30]^.

Some values of IC50, copy number variation, and mutation profiles in both datasets were missing. A pre-processing procedure was applied, according to Lu et al.^[@CR2]^ to impute the missing values, which is fully described in "[Pre-processing to impute the missing data](#Sec12){ref-type="sec"}". After applying the pre-processing steps, the GDSC dataset contained 98 drugs and 555 cell lines from 19 cancer types, as defined by The Cancer Genome Atlas (TCGA)^[@CR31]^, and the CCLE dataset contained 24 drugs and 363 cell lines from 22 cancer types as defined by TCGA. Furthermore, several types of information about drugs were obtained from the following databases:The fingerprints of canonical simplified molecular-input line-entry (SMILES) were obtained from PubChem^[@CR30]^.The target proteins were collected from GDSC, DrugBank^[@CR32]^, and literature.The KEGG-pathways related to the drugs were downloaded from the STiTCH database^[@CR33]^.A brief description of the collected data is presented in Table [1](#Tab1){ref-type="table"}.Table 1The number of collected samples and features.DatasetCell lineDrugTissue typesExpression profileMutation profileCopy number variationDrug fingerprintTarget proteinKEGG pathwayCCLE363242219,3891,66724,96088176124GDSC555981911,7125424,959881----The cell line features such as gene expression profile, mutation profile, copy number variation, tissue types, drug names, and drug response values were downloaded from PharmacoGx package, Drug fingerprints were obtained from pubchem, target proteins were gathered mainly from GDSC and DrugBank, and KEGG pathways were obtained from STiTCH database.

Hyper-parameter tuning {#Sec4}
----------------------
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Performance of ADRML prediction {#Sec5}
-------------------------------

We investigated the effects of using different similarity constraints on ADRML performance. Several cell line similarities based on gene-expression, mutation, and copy number variation, and multiple drug similarities based on chemical substructure, target proteins, and KEGG pathways were considered as the constraints of manifold learning.

Table [2](#Tab2){ref-type="table"} summarizes the performance of ADRML for every combination of cell line and drug similarity. Each pair of cell line and drug similarity is shown in one row and the columns show the computed criteria. Clearly, ADRML yields both accurate and robust performance in each scenario, because the results of all conditions are quite high and close to each other. However, it achieves the best results using similarity of cell lines based on gene expression and similarity of drugs based on target proteins, which yields $\documentclass[12pt]{minimal}
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In order to investigate ADRML performance on each drug, we depicted the drug-wise correlation plots. Figures [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} illustrated the pearson correlation between the observed and the predicted $\documentclass[12pt]{minimal}
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                \begin{document}$$ \log IC50 $$\end{document}$ for four drugs in CCLE and GDSC datasets, respectively. The figures show high drug-wise *PCC* and validate that ADRML can predict drug responses with high correlation to the real responses. The majority of data in these scatter plots are centered near the fitted line. It is notable that the outliers are natural due to the technical noises in gene expression data, or inconsistency of drug responses in CCLE and GDSC^[@CR5],[@CR25],[@CR34],[@CR35]^. Further plots for drug-wise *PCC* of GDSC are shown in Supplementary Figs. [S1](#MOESM1){ref-type="media"}--[S98](#MOESM1){ref-type="media"} and the drug-wise *PCC* of CCLE are shown in Supplementary Figs. [S99](#MOESM1){ref-type="media"}--[S122](#MOESM1){ref-type="media"}.Figure 2Drug-wise *PCC* for 4 drugs in CCLE. The computed *PCC* is illustrated in lower right corner of each plot.Figure 3Drug-wise *PCC* for 4 drugs in GDSC. The computed *PCC* is illustrated in lower right corner of each plot.

Comparison of prediction performance with state-of-the-art methods {#Sec6}
------------------------------------------------------------------

For comprehensive evaluation of ADRML's performance, we compared it to other recent state-of-the-art methods, namely, CDRscan^[@CR21]^, CDCN^[@CR25]^, SRMF^[@CR1]^, and CaDRReS^[@CR19]^. The implementations of all methods were obtained from the available codes referred to in their papers. In order to have a fair comparison, we conducted all evaluations in the same setting and using the same datasets. The comparison was made on the average performance of the models over 30 repetitions of fivefold cross-validation with tuned hyper-parameters.

It should be noted that the hyper-parameters of CaDRReS cannot be fully tuned, due to its high time complexity. The hyper-parameters for CaDRReS is assumed according to its paper and authors' suggestion.

The features used for cell lines and drugs are different in these methods. For each method, the required features, as mentioned in their paper, are provided from the benchmark datasets described in \"[Benchmark datasets and collected features](#Sec3){ref-type="sec"}\".

In addition to the mentioned methods, K-nearest neighbor (KNN) with $\documentclass[12pt]{minimal}
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                \begin{document}$$ d_j $$\end{document}$ was considered as the concatenated vector of *i*th row of *simC* and *j*th column of *simD*. All types of cell line similarities and drug similarities were considered as *simC* and *simD*, respectively. The complete report of KNN performance on various types of similarities are provided in Supplementary Table [S1](#MOESM1){ref-type="media"}. KNN obtained the best performance on gene expression similarity of cell lines and chemical substructure similarity of drugs.

Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} present the performance of the mentioned methods on CCLE and GDSC, respectively. Additionally, the scatter-plots with fitted lines for the predictions of the mentioned methods on CCLE are presented in Supplementary Figs. [S123](#MOESM1){ref-type="media"}--[S128](#MOESM1){ref-type="media"}.Table 3Comparison of methods' performance on CCLE dataset.MethodCell line similarityDrug similarityRMSE$\documentclass[12pt]{minimal}
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The results of baseline method (KNN) in both datasets were not too far from the state-of-the-art methods, which means that improving the results is challenging. In CCLE dataset, SRMF achieved the best *RMSE* and favorable *PCC*; however, it achieved $\documentclass[12pt]{minimal}
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                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ {R^2 }$$\end{document}$PCCADRMLGene expressionChemical0.73**0**.**750**.**88**CDRscanMutationChemical0.760.720.83CDCNGene expressionChemical0.770.720.85SRMFGene expressionChemical**0**.**20**0.620.85CaDRReSGene expression--0.490.340.57KNNGene expressionChemical0.990.550.78The methods were evaluated by averaging over 30 repetitions of using fivefold cross-validation on cell line-drug pair. The best result of each criterion is shown in boldface.

In the case of the GDSC dataset, SRMF obtained the best *RMSE* and moderate $\documentclass[12pt]{minimal}
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In addition to the mentioned analysis, we investigated whether using other types of cell line similarities and dug similarities would aid in improving the results of other methods. To this aim, we executed CDCN, SRMF, CaDRReS, and KNN on all types of similarities. It is worth mentioning that CDRscan receives binary feature matrices as the input and the dimension of binary feature vectors of drugs in CCLE and GDSC datasets were not appropriate for the designed CNNs in CDRscan; therefore, it is not applicable to perform CDRscan on other types of similarities. Other methods (CDCN, SRMF, CaDRReS, and KNN) receive the similarity matrices as the input. Moreover, CaDRReS gets only the cell line similarity, and it does not obtain any drug similarity matrix from the input.

The entire report of the performance criteria measured for the performance of the mentioned methods is presented in Supplementary Table [S1](#MOESM1){ref-type="media"}. It can be seen that the performance of other methods almost does not improve using other similarities in comparison to their proposed similarities. Often, with respect to a particular pair of cell line similarities and drug similarities, SRMF obtains the best *RMSE*. At the same time, ADRML achieves best $\documentclass[12pt]{minimal}
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All in sum, ADRML performed better than other state-of-the-art methods on both CCLE and GDSC in terms of $\documentclass[12pt]{minimal}
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                \begin{document}$$ R^2 $$\end{document}$ and *PCC*. These achievements further substantiate ADRML performance.Figure 4Tissue types in CCLE. The number of cell lines in each tissue type is shown in parenthesis.

Removing redundant cell lines from CCLE and GDSC {#Sec7}
------------------------------------------------

CCLE dataset contains 363 cell lines from 22 different tissue types. The number of cell lines in each tissue type is shown in Fig. [4](#Fig4){ref-type="fig"}. The least frequent tissue types (Biliary tract and prostate) contain one cell line, and the most frequent tissue type (Lung) comprises 76 cell lines. Since the cell lines from the same tissue may have high similarity, this may lead to redundancy. Thus, it is better to eliminate the redundancy within each tissue type and based on the number of cell lines from that tissue. In order to remove the redundancy in each tissue type, we filtered out the cell lines that are very similar to other cell lines. In this way, we excluded the cell lines with high similarity to other cell lines in the same tissue type.

The detailed procedure of removing redundant cell lines is described in "[Finding the most redundant cell lines](#Sec17){ref-type="sec"}". This procedure led to eliminating 64 cell lines and the remaining 299 cell lines from CCLE. The remaining cell lines comprise the purified CCLE dataset without redundancy. The list of remaining and excluding cell lines are reported in Supplementary Table [S2](#MOESM1){ref-type="media"}. To analyze the performance of ADRML and other state-of-the-art methods on the new dataset, we executed these methods using 30 repetitions of fivefold cross-validation. Table [5](#Tab5){ref-type="table"} demonstrates the performance of methods on the new dataset. It can be seen that ADRML outperforms other methods with respect to $\documentclass[12pt]{minimal}
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Figure 5Tissue types in GDSC. The number of cell lines in each tissue type is shown in parenthesis.

Moreover, the GDSC dataset comprises 555 cell lines from 19 tissue types. Various tissue types have different numbers of cell lines which are shown in Fig. [5](#Fig5){ref-type="fig"} To remove the redundant cell lines from GDSC, the procedure described in "[Finding the most redundant cell lines](#Sec17){ref-type="sec"}" was applied on the GDSC, resulting in eliminating 103 cell lines and preserving 452 cell lines. The remaining cell lines form the purified GDSC dataset with lower redundancy. The list of remaining and excluding cell lines are reported in Supplementary Table [S2](#MOESM1){ref-type="media"}. The performance of methods on the new GDSC dataset using 30 repetitions of fivefold cross-validation is represented in Table [6](#Tab6){ref-type="table"}. It can be seen that SRMF obtained the best *RMSE*, CDCN achieved the best $\documentclass[12pt]{minimal}
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It can be inferred from the comparison results in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"} with the results in the Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"} that the performance of models declines a bit when the redundant cell lines were removed. This issue may be due to the reduction in sample size or the existence of bias before removing redundancy of cell lines.

Moreover, we applied the redundancy removal procedure with different thresholds $\documentclass[12pt]{minimal}
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                \begin{document}$$ (\theta ) $$\end{document}$ to investigate the performance of ADRML on different levels of redundancy removal. Furthermore, this procedure is repeated based on gene expression similarities of cell lines. Table [7](#Tab7){ref-type="table"} represents the number of remaining cell lines according to the various values of threshold.Table 7The number of remaining cell lines in CCLE and GDSC after applying redundancy removal procedure with different levels of strictness (threshold) based on copy number variation and gene expression.ThresholdDatasetRemained cell lines based on copy number variationRemained cell lines based on gene expression0.01CCLE721110.05CCLE1161610.1CCLE1942090.15CCLE2452450.2CCLE2992770.25CCLE3253030.3CCLE3393220.35CCLE3513450.01GDSC781070.05GDSC1612090.1GDSC2662930.15GDSC3633620.2GDSC4524350.25GDSC5014800.3GDSC5295090.35GDSC547532

ADRML performance was evaluated on each of the resulting datasets after redundancy removal based on various levels of strictness. Figure [6](#Fig6){ref-type="fig"}a,b illustrate the *PCC* values of ADRML assessed using 5-fold cross-validation on the purified datasets. These figures verify that the trend of ADRML performance is almost the same on purified datasets based on copy number variation and gene expression. ADRML achieves the best *PCC* on the strictest threshold which removes a lot of cell lines and adding other cell lines declines its *PCC*. Moreover, the ADRML's *PCC* on purified CCLE datasets first increased sharply and then decreased by lowering the level of strictness in redundancy removal.Figure 6Performance of ADRML on purified datasets with different levels of strictness. The purified datasets were obtained after redundancy removal with certain thresholds. Each panel shows the *PCC* of ADRML assessed using 5-fold cross-validation on the purified datasets.

Analysis of association between drugs and signaling pathways {#Sec8}
------------------------------------------------------------

To demonstrate that the prediction of ADRML is meaningful and rational, we investigated the correlation between the predicted drug responses and pathway activity scores for several Biocarta Pathways from MsigDB^[@CR37]^. The detailed procedure is described in "[Computing association of drugs and signalling pathways](#Sec18){ref-type="sec"}". Figure [7](#Fig7){ref-type="fig"} visualizes the association between drugs and signaling pathways for 24 drugs in the CCLE dataset and 25 Biocarta pathways. The entire association values are provided in Supplementary Table [S3](#MOESM1){ref-type="media"}. There are numerous pieces of evidence in the literature for these correlations, some of which are provided here.
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*Irinotecan* response has a very significant positive correlation with the activity score of *P*53. *Irinotecan* is a topoisomerase I inhibitor, which is frequently used for anticancer therapy. The previous study on human hepatocellular carcinoma (HCC) cell lines for the investigation of the apoptotic mechanisms of *Irinotecan* has revealed that it significantly activates *P*53^[@CR45]^. Additionally, the positive correlation of *Irinotecan* response and *EGFR* pathway is supported by several pieces of research. They have shown the resistance to *Irinotecan* is connected with the increased expression of *EGFR*^[@CR46]^ and have admitted that *Irinotecan* upregulates the *EGFR* pathway^[@CR47]^. Also, *Panobbinostat* which is a potent inhibitor of deacetylases and HSP90^[@CR48]^, revealed a high significant positive correlation with $\documentclass[12pt]{minimal}
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                \begin{document}$$ TGF\beta $$\end{document}$^[@CR48]^.Figure 7Correlation of pathway activity scores and drug responses. The drugs are shown in rows, and pathways are shown in columns. The positive correlations are represented in red and negative correlations are represented in blue. The intensity of the color indicates the extent of correlation.Table 8The Literature evidence for some of sensitive predictions of ADRML about novel cell line-drug pairs.Cell lineDrugCell line cancer typeDrug indicationEvidenceHOP-92ParthenolideNon-Small Cell Lung CancerPan-cancerJanganati et al.^[@CR49]^MDA-MB-468ParthenolideBreast cancerPan-cancerJanganati et al.^[@CR49]^HCT-116ParthenolideColon cancerPan-cancerJanganati et al.^[@CR49]^MKN45RoscovitineGastric adenocarcinomaPan-cancerTrenti et al.^[@CR50]^AGSRoscovitineGastric adenocarcinomaPan-cancerTrenti et al.^[@CR50]^These cell line-drug pairs has unknown IC50 in the training dataset and ADRML predicted them as the sensitive prediction. The evidence papers for these predictions are represented in the last column.Table 9ADRML sensitive predictions for novel cell line-drug pairs verified by the latest release of GDSC.Cell lineDrugCell line cancer typeDrug indicationSK-MEL-24NSC-87877MelanomaMelanomaSK-MEL-3NSC-87877MelanomaMelanomaTK10ErlotinibRenal cell carcinomaNon-small cell lung cancer (NSCLC) and pancreatic cancerSW684WH-4-023FibrosarcomaPan-cancerSW982BMS-509744Synovial sarcomaPan-cancerSK-LMS-1CMKVulvar leiomyosarcomaPan-cancerSW982A-770041Synovial sarcomaSarcomaThese pairs had unknown IC50 in the training dataset and were predicted as a sensitive pair by ADRML. The latest release of GDSC reported these pairs as the sensitive pairs.

Case studies {#Sec9}
------------

We conducted case studies on GDSC cell-line-drug pairs with unknown IC50 values. To do this, we did not impute the missing values in the *IC*50 matrix and trained ADRML with all known drug responses. For each drug, the predictions of ADRML on unknown pairs were partitioned into four quantiles, and the cell lines in the first and last quantiles were considered as the sensitive and resistant cell lines for that drug, respectively. The complete list of sensitive and resistant predicted associations are provided in Supplementary Tables [S4](#MOESM1){ref-type="media"} and [S5](#MOESM1){ref-type="media"}, respectively. The sensitive associations were inquired into both the literature and the latest release of GDSC (released Feb. 2020). Table [8](#Tab8){ref-type="table"} represents the supportive pieces of evidence for ADRML predictions in Literature. Table [9](#Tab9){ref-type="table"} incorporates some of the cell line-drug pairs that had unknown *IC*50 values in the previous data extracted from GDSC, and now the drug response value for these pairs are available in the latest release of GDSC.

Discussion {#Sec10}
==========

In this study, we proposed a computational model for predicting anticancer drug response, using manifold learning, called ADRML. The model combines three sets of information, including known drug responses, cell line similarity, and drug similarity, to infer the novel predictions. The main contribution of this paper is evaluating the influence of various types of cell line similarities and drug similarities on the prediction performance. We collected various features for cell lines and drugs from CCLE, GDSC, STiTCH, PubChem, and Drugbank. Here, we investigated nine different scenarios using three cell line similarities based on gene expression, mutation, and copy number variation, and three drug similarities based on the chemical substructure, target proteins, and KEGG pathways. The performance of ADRML was investigated using fivefold cross-validation on cell line-drug pairs. The best performance was obtained using gene expression data about cell lines and target protein data about drugs, which was more accurate than the previously proposed methods. We also investigated the performance of other state-of-the-art methods and KNN (with k = 1) as the baseline method on various types of similarities and showed that their best performance was achieved using the similarities that were suggested in their papers.

Another contribution of this paper was the purification of CCLE and GDSC benchmarks via removing redundant cell lines. The purified benchmarks were also used for assessing the methods' performance. The results showed that excluding redundant cell lines declines the methods' performance, which may be due to the reduction of sample size or removing bias from the database.

It was interesting that KNN with k = 1 as a simple baseline method shows favorable results and outperforms some more complicated methods, especially on the purified datasets. However, it should be noted that sophisticated methods' performance declines when the data size is not sufficient. A complicated method needs a massive amount of data to train well and gets a good grasp of predicting outputs from inputs. For example, Chang et al.^[@CR21]^ have provided CDRscan with more cell lines and drugs than used in this paper and have trained CDRscan with 95% of its data (despite 80% of data in this paper). Therefore, the reported $\documentclass[12pt]{minimal}
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                \begin{document}$$ R^2 $$\end{document}$ in^[@CR21]^ is better than the results reported in this paper. One can conclude that providing more informative data may enrich the training data and lead to better training the complex models. It is noteworthy that due to the challenging inherent of the problem, little improvements in results is welcome and useful.

The proposed method in this study outperformed other methods in terms of two criteria $\documentclass[12pt]{minimal}
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                \begin{document}$$ R^2 $$\end{document}$ and *PCC* in most comparison scenarios. The predicted drug response values revealed high correlations with observed drug responses and suggested meaningful clues about drug mechanisms in activation/inhibition of pathways. Moreover, the reliable literature evidence supports the predictions of ADRML about novel cell line-drug pairs. As a consequence, the promising results of ADRML verified its efficiency in predicting anticancer drug prediction and imputation.

Method {#Sec11}
======

The proposed method includes five steps:Pre-processing to impute missing dataCalculating various types of similarity matrices for cell lines and drugsNormalizing the similarity matricesSimilarity-constrained manifold learning to factorize the IC50 matrix into low-rank latent matricesEstimating Unknown IC50 values using the latent matricesThe overall workflow of ADRML is illustrated in Fig. [8](#Fig8){ref-type="fig"}.
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                \begin{document}$$ d_j $$\end{document}$.Figure 8The overall workflow of ADRML. (**A**) Collecting various types of cell lines and drugs features. Further steps can be executed for each pair of cell line feature types and drug feature types. (**B**) Pre-processing the collected feature by removing the features with missing data for more than half samples and then imputing the remaining missing values. (**C**) Computing various types of cell line similarities and drug similarities using similarity functions. (**D**) Normalizing the similarity matrices using symmetric normalized Laplacian. (**E**) The IC50 matrix constructed from known IC50 values is factorized into two low-rank latent matrices with constraints of the similarity matrices. The unknown IC50 values can be predicted by multiplying the latent matrices.

Pre-processing to impute the missing data {#Sec12}
-----------------------------------------

Several steps were done to impute the missing data. First, the features that were missed in the majority of cell lines are removed. Second, the cell lines that contain missing values for more than half of the features were excluded. The other missing values were imputed using a k-nearest neighbor approach. To this aim, the distance measure between cell lines was defined as the Euclidean distance of their expression profiles because there is no missing in expression features of the cell line; thus, the distance can be calculated for each pair of cell lines. The distance between $\documentclass[12pt]{minimal}
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Similarity matrices construction and normalization {#Sec13}
--------------------------------------------------

For computing the similarity score of two cell lines (or drugs), the *PCC* and Jaccard-index (JI) were regarded as the similarity function, which are elaborated in the following.$$\documentclass[12pt]{minimal}
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                \begin{document}$$ SimC_{MUT} $$\end{document}$ is the similarity matrix of cell lines based on their mutation profiles. $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$\begin{aligned} SimC_{MUT}(c_i,c_j) =JI(MUT_{c_i},MUT_{c_j}) \end{aligned}$$\end{document}$$Furthermore, three types of similarity matrices for drug based on Pubchem SMILES (*CHEM*), target proteins (*TRGT*), and KEGG pathways (*KEGG*) were calculated as follows. It is notable that all drug features are binary-valued; thus, *JI* was used for measuring the similarity of drugs based on each type of information.$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$ SimD_{CHEM} $$\end{document}$ is the similarity matrix of drugs according to their chemical substructure fingerprints. $$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
                \begin{document}$$\begin{aligned} SimD_{CHEM}(d_i,d_j) =JI(CHEM_{d_i},CHEM_{d_j}) \end{aligned}$$\end{document}$$$\documentclass[12pt]{minimal}
                \usepackage{amsmath}
                \usepackage{wasysym} 
                \usepackage{amsfonts} 
                \usepackage{amssymb} 
                \usepackage{amsbsy}
                \usepackage{mathrsfs}
                \usepackage{upgreek}
                \setlength{\oddsidemargin}{-69pt}
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Manifold learning with similarity constraints {#Sec14}
---------------------------------------------

We constructed a bipartite graph with two parts: drugs and cell lines. The weight of edges between cell line $\documentclass[12pt]{minimal}
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                \begin{document}$$ n, \ m $$\end{document}$ are the number of cell lines and drugs, respectively. We used the manifold learning to factorize the drug response matrix *R* in two latent matrices $\documentclass[12pt]{minimal}
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The initial goal is to find matrices *P* and *Q*, such that each drug response value is obtained by inner product of corresponding latent vectors, i.e., $\documentclass[12pt]{minimal}
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                \begin{document}$$ \mu $$\end{document}$ is the regularization coefficient. The regularization terms prevent these matrices to grow dramatically; therefore, the over-fitting issue may not occur. These regularization terms help to reduce the variance and increase the stability and generalization capabilities of the model^[@CR52]^.

Manifold learning studies^[@CR53],[@CR54]^ have shown that the mapping of data to a lower dimensional space can conserve the topological structure of data. Since $\documentclass[12pt]{minimal}
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                \begin{document}$$SimD_{KEGG}\} $$\end{document}$. Two last terms are minimized when the feature vectors of cell line (or drug) pairs with high similarity are mapped to not distant latent vectors. Therefore, the topological distance of cell lines (or drugs) is maintained while mapping to the lower dimensional space.

### Iterative optimization rules {#Sec15}

The latent matrices *P*, *Q* must be obtained by minimizing the loss function in [15](#Equ15){ref-type=""}. We used the iterative Newton's method^[@CR55]^ to update *P*, *Q* matrices:$$\documentclass[12pt]{minimal}
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Moreover, the manifold learning was applied on the transpose of response matrix, i.e. all the above procedure was repeated for factorizing $\documentclass[12pt]{minimal}
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Evaluation criteria {#Sec16}
-------------------

We measured the performance ADRML using 5-fold cross-validation on cell line-drug pairs. To do this, each pair of $\documentclass[12pt]{minimal}
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                \begin{document}$$ (c_i,d_j) $$\end{document}$ was considered as a sample. Then, the set of all samples was partitioned randomly into five almost equally-sized subsets (fold). One fold was considered as the test data and the other folds were regarded as the training data. The evaluation was computed for the test data. This procedure was iterated until each fold was considered once as the test data. Finally, the average of evaluation criteria over these five iterations denoted the model performance. Evaluation of ADRML is summarized as pseudo-code and shown in Fig. [9](#Fig9){ref-type="fig"}.Figure 9The pseudo-code for evaluation of ADRML performance.

To avoid randomness and reducing variance, the model performance was averaged over 30 randomly repetition of 5-fold cross-validation. The evaluation criteria include *RMSE*, $\documentclass[12pt]{minimal}
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                \begin{document}$$ {\bar{IC}}_{real}, {\bar{IC}}_{pred} $$\end{document}$ are their mean values, and \|*Test*\| is the number of samples in the test set. Each criterion evaluates the model performance from a different point of view. Therefore, it is possible to obtain results which led to promising values of one criterion and unfavorable values for other criteria.

Finding the most redundant cell lines {#Sec17}
-------------------------------------

In order to eliminate the redundancy from the dataset, the cell lines in each tissue type that have high similarity to the majority of cell lines in that tissue type were considered as the most redundant cell lines and excluded from the dataset. To do this, the minimum (Q0), first quantile (Q1), second quantile (Q2), third quantile (Q3), and maximum (Q4) values for each type of cell line similarity in all tissue type were calculated, which are shown in Supplementary Tables [S6](#MOESM1){ref-type="media"} and [S7](#MOESM1){ref-type="media"}. The diversity of cell lines was projected better concerning the values of copy number variation similarities, since there was a vast difference between the quantile values with respect to this similarity. Therefore, the third quantile of copy number variation similarities between the cell lines were computed in each tissue type *t* (denoted by *Q*3(*CNV*, *t*) ). The cell line *c* in tissue type *t* was excluded if it had the similarity higher than *Q*3(*CNV*, *t*) with more than $\documentclass[12pt]{minimal}
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Computing association of drugs and signalling pathways {#Sec18}
------------------------------------------------------

The association between drug and pathway was computed by the *PCC* of drug response values and pathway activity scores. To do this, we considered all Biocarta signaling pathways and eliminated the pathways that the gene expression data of more than 10% of its genes were not provided. Therefore, we considered 107 Biocarta pathways for CCLE dataset. The pathway activity score for cell line $\documentclass[12pt]{minimal}
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                \begin{document}$$\begin{aligned} AS(c_i,p_j)=\sum _{g_l \in p_j} \log \dfrac{EXPR(c_i,g_l)}{median_c(EXPR(c,g_l))} \end{aligned}$$\end{document}$$where $\documentclass[12pt]{minimal}
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                \begin{document}$$ g_l $$\end{document}$ in all cell lines. Thus, the score of a cell line in activating a pathway denotes the total amount of change in gene expression with respect to the median expression.
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